BGNE - BeiGeneAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $335.96 | Open | $339.26 |
| Volume | 502.4K | Market Cap | 30.549B |
| Yield | Last Dividend |
| China National Medical Products Administ... | 01/13/21 |
| BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene's anti-PD-1 antibody received approval in China in first-line advanced squamous n... | |
| Why BeiGene, T2 Biosystems And Amneal Ar... | 01/12/21 |
| BeiGene (NASDAQ: BGNE ) shares are trading higher ??? Full story available on Benzinga.com | |
| The Daily Biotech Pulse: GSK, Vir To Sta... | 01/12/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) 10X... | |
| BeiGene Announces Collaboration with Nov... | 01/11/21 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and Novartis enter into a collaboration to develop, manufacture and commercialize... | |
| Novartis expands Oncology pipeline with ... | 01/11/21 |
| Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and??? | |
| Strand Therapeutics and BeiGene Enter in... | 01/11/21 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--Strand Therapeutics and BeiGene entered an option and license agreement aimed at developi... | |
| BeiGene Announces Inclusion of Three Inn... | 12/27/20 |
| BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces inclusion of three innovative oncology products in China Nationa... | |
| BeiGene Announces the Approval in China ... | 12/07/20 |
| BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces that BLINCYTO?? (blinatumomab) for injection has been approved in China... | |
| BeiGene Presents Clinical Data on BRUKIN... | 12/07/20 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene announces clinical data on BTK inhibitor BRUKINSA (zanubrutinib) in B-cell malig... | |
| BeiGene Announces Data on BRUKINSA?? (Za... | 12/06/20 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene presents data on BTK inhibitor BRUKINSA in marginal zone lymphoma and chronic ly... | |
| BeiGene Launches Proposed Public Offerin... | 12/01/20 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focus... | |
| Zymeworks Announces Expansion of Zanidat... | 12/01/20 |
| VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biothe... | |
| BeiGene Announces the Approval of XGEVA?... | 11/19/20 |
| BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces the second approval of XGEVA?? (denosumab) in China. | |
| BeiGene (NASDAQ:BGNE) Price Target Raise... | 11/19/20 |
| BeiGene (NASDAQ:BGNE) had its price target hoisted by research analysts at SVB Leerink from $240.00 to $327.00 in a note issued to investors on Thursd... | |
| BeiGene Announces that RATIONALE 303 Tri... | 11/17/20 |
| CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BGNE--Global Phase 3 trial of tislelizumab in second- or third-line non-small cell lung ... | |
| EUSA Pharma and BeiGene Announce Accepta... | 11/09/20 |
| HEMEL HEMPSTEAD, England & BEIJING, China, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160)... | |
| BeiGene Reports Third Quarter 2020 Finan... | 11/05/20 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene reports recent business highlights, anticipated upcoming milestones and financial... | |
| BeiGene Announces Data on BRUKINSA?? (Za... | 11/05/20 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH--BeiGene announces data on BRUKINSA?? (zanubrutinib) and tislelizumab to be presented at th... | |
| Here's how 9 leading drugmakers are raci... | 10/27/20 |
| Summary List Placement In the sprint for an effective coronavirus treatment, several of the biggest drugmakers in the world have all landed on the sam... | |
| Insider Selling: Beigene Ltd (NASDAQ:BGN... | 10/23/20 |
| Beigene Ltd (NASDAQ:BGNE) insider Xiaodong Wang sold 5,000 shares of the firm???s stock in a transaction on Friday, October 16th. The stock was sold a... | |
| Xiaodong Wang Sells 5,000 Shares of Beig... | 10/21/20 |
| Beigene Ltd (NASDAQ:BGNE) insider Xiaodong Wang sold 5,000 shares of the firm???s stock in a transaction dated Friday, October 16th. The shares were s... | |
| Beigene Ltd (NASDAQ:BGNE) Insider Sells ... | 10/20/20 |
| Beigene Ltd (NASDAQ:BGNE) insider Xiaodong Wang sold 5,000 shares of Beigene stock in a transaction on Friday, October 16th. The shares were sold at a... | |
| The Daily Biotech Pulse: J&J Pauses Coro... | 10/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X... | |
| The Daily Biotech Pulse: Pfizer, BioNTec... | 10/06/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) 10X ... | |
| BioAtla and BeiGene Revise Global Develo... | 10/06/20 |
| SAN DIEGO & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene will hold an exclusive license to the global clinical development and... | |
| The Daily Biotech Pulse: Amag Spikes On ... | 10/01/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) Ac... | |
| The Daily Biotech Pulse: Eton Snags Seco... | 09/30/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Ac... | |
| The Daily Biotech Pulse: FDA Nod For Pfi... | 09/29/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) 10... | |
| Leap Therapeutics and BeiGene Announce F... | 09/21/20 |
| CAMBRIDGE, Mass. and BEIJING, Sept. 21, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targ... | |
| BeiGene Presents Data at ESMO Virtual Co... | 09/17/20 |
| CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene presents Phase 3 data of tislelizumab in non-squamous non-small cell lung cancer ... | |
| Buy rating | 12/08/20 |
| Ladenburg Thalmann upgrades from Neutral to Buy rating and announces Price Target of $278.00 | |
| Strong Buy rating | 11/19/20 |
| SVB Leerink maintains Outperform rating and raises Price Target from $240.00 to $327.00 | |
| Strong Buy rating | 11/11/20 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $270.00 to $310.00 | |
| Sell rating | 11/06/20 |
| Piper Sandler downgrades from Neutral to Underweight rating and announces Price Target of $185.00 | |
| Strong Buy rating | 11/06/20 |
| SVB Leerink maintains Outperform rating and raises Price Target from $210.00 to $240.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| WIDE AWAKE | JOHN KROLIKOWSKI JR | 79.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
